The IMWG present recommendations on imaging both in clinical practice and in the trial setting to help standardise the best imaging methods to use as myeloma patients progress through different disease stages.
As whole-body MRI is listed in NICE guidance as the recommended first line imaging in patients with suspected myeloma, this paper outlines a clinical protocol: the Myeloma Response Assessment and Diagnosis System (MY-RADS), for its use and interpretation.
The Bone group of the IMWG present recommendations for the use of whole body low-dose CT in patients with myeloma and other plasma cell disorders, as an imaging method for assessing bone disease in these patients.
This paper, produced by an expert panel of the International Myeloma Working Group (IMWG) reviews the assessment of disease response and endpoints for clinical trials, and provides updated response categories of minimal residual disease negativity.
These updated guidelines, produced by the British Society of Haematology and Myeloma UK summarise a national consensus for the use of imaging in the diagnosis and management of myeloma patients.
Chantry et al. (2017) British Journal of Haematology
DownloadThis paper, written by the International Myeloma Working Group (IMWG), reviews the current evidence, and provides recommendations for the optimal use of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and related diseases, including smouldering myeloma and solitary plasmacytoma.
This paper, written by an expert panel on behalf of the International Myeloma Working Group, provides consensus guidelines for the use of the serum free light chain assay in the diagnosis and management of clonal plasma cell disorders.
Download